ACADIA Pharmaceuticals Inc. (ACAD)

20.72
NASDAQ
Prev Close 21.15
Day Low/High 20.24 / 21.42
52 Wk Low/High 20.12 / 58.72
Exchange NASDAQ
Shares Outstanding 160.05B
Market Cap 3.38B
P/E Ratio N/A
Div & Yield N.A. (N.A)
4 Possible Acquisition Targets in Biotech

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

My Takeaways and Observations

I started the day with an updated and still ursine market update: "Hey, Let's Be Careful Out There."   A new investment short -- England, via iShares MSCI United Kingdom (EWU).  EWU as a short went on my Best Ideas List. Jim Chanos and I are thinkin...

Acadia downgraded at Leerink

4 Possible Biotech M&A Targets

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.

My Takeaways and Observations

Today and yesterday are good examples of the fondness of crowds, and that buyers live higher and sellers live lower. Stocks closed at the day's highs, despite a reversal in the price of crude oil and some weak domestic data and disappointing retail ...

My Takeaways and Observations

Another strong market day.  The issue of taxes was front and center today. Here are some of my takes: My Take on Corporate Taxes  Man Up, Allergan Shareholders  Who Loses in Pfizer/Allergan Deal's Demise?  I remain manifestly bearish, in the belief ...

Today's Takeaways and Observations (Early Edition)

I started the day today by dissing the banks.                  Then, I unfriended Facebook (FB) by making it my Short Trade of the Week. Finally, I offered another critical post about auto stocks. Hey, at least I'm consistent! And at least I like Op...

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

My Takeaways and Observations

Take this, bulls!  This, too!  I ended the day with my highest net short exposure in more than 12 months. Committed in view, or to be committed? You decide. The U.S. dollar declined in value today. This seems to be a key element of the bulls' argume...

U.S. Futures Have Strong Start to Week

U.S. Futures Have Strong Start to Week

U.S. futures are climbing Monday after major indices experienced a dip in trading last week.

Today's Takeaways and Observations (Early Edition)

I started the day with a cautionary tale (click here and here), then made Apple (AAPL) my Short Trade of a Week. I also made a hard decision to take all nine banks off of my "Best Long Ideas" list and sell off some of my bank holdings. My takeaways ...

Biotech Biowreck!

The collapse of Valeant Pharmaceuticals (VRX) has cast a pall over the entire biotech sector today. The iShares Nasdaq Biotechnology ETF (IBB) is down by about 3%, led by VRX plus significant drops in Allergan (AGN), Celgene (CELG) and Gilead Scienc...

My Takeaways and Observations

I remain "all in short," positioned on Friday afternoon.   My message for the day this morning? "Don't worship at the church of what's happening now."  The key insight today was the flight to safety. More risk off might lie ahead. Thanks for the nic...

Small-Cap Friday: ACADIA Pharmaceuticals

Small-Cap Friday: ACADIA Pharmaceuticals

I like the biopharma's risk/reward on potential sales of Nuplazid.

My Takeaways and Observations

A win for the bulls. I outlined my cautious view in my opener.  I sold a number of longs and reduced my long side today.   I sold my biotech basket for a good two-and-a-half-week gain.  I reduced my bank longs from large to between small and medium ...

Selling Biotechs for Some Nice Gains

I'm reducing the size of my biotech basket by selling across the board following some very large gains. In fact, I expect to completely eliminate my holdings if we see any further increases. Today's gains have been truly breathtaking. We've seen 5% ...

Biotech Goes From Goat to Hero

Several members in my new biotech basket have continued to make notable upside moves throughout the recent rally, including today. Winners include Acadia Pharmaceuticals (ACAD), Aerie Pharmaceuticals (AERI), Cempra (CEMP), Intrexon (XON), Portola Ph...

My Takeaways and Observations

If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...

My Takeaways and Observations

I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here.  Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...

My Takeaways and Observations

Mr. Market has provided outstanding opportunities year to date. I am happy with the way I have been trading the market, taking advantage of the market without memory from day to day and staying with my game plan in an unemotional way. The banks -- e...

Takeaways and Observations

Hello, all -- I'm back! Great job yesterday by Chris "Not the Designer" Versace in subbing for me. My takeaways and observations regarding yesterday's action: St. Louis Fed President James Bullard is full of bull. Ray Dalio of hedge fund Bridgewater...

Biotech Breakout

Given my risk-averse profile, I made the unusual move last week of buying a basket of biotech stocks. And yesterday, I noted that Biotech Could Be Close to a 'Double Bottom': "I recently created a basket of a dozen speculative and conservative biote...

Biotech Goes From 'Zero' to 'Hero'

My basket of 12 biotech stocks is rocking this morning! We're seeing a 9% rally in Cempra (CEMP), a 5% rise in Intrexon (XON), a 4% gain in Acadia Pharmaceuticals (ACAD) and a 3% boost in Sage Therapeutics (SAGE).

My Takeaways and Observations

This might be the most hated market rally in months.  As I have been commenting, we got deeply oversold, support held and machines/algos did the rest! The typical correlation between SPDR S&P 500 ETF (SPY) and the inverse iShares 20+ Year Treasury B...

Today's Takeaways and Observations

Chuck (Judge Smails) thoroughly embarrassed me into making a day's end post, noting that when I was younger I had the energy to still complete Takeaways. He went on to write that my current age is slowing me down. I know (hope!) you were kidding and...

Buying Biotechs

The iShares Nasdaq Biotechnology ETF (IBB) has tumbled from nearly $400 a share early last summer to around $240 at last check, so I'm taking advantage of today's market schmeissing to purchase a small position in a biotech (biowreck?). I'm buying a...

Acadia upgraded at Piper

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Unilever (UL) shares are up over 7% so far this year and the consumer staples giant will continue to perform well as it expands its reach in the emerging markets.